| Code | 8417D | ||||||||||
| MA number | 59/0323/18-S | ||||||||||
| Product Form: | cps dur 21(21x1)x25 mg (blis.OPA/Al/PVC/Al - perfor.blister) | ||||||||||
| MA Status: | D - Marketing Authorisation valid for an unlimited period | ||||||||||
| Type of procedure: | Decentralised | ||||||||||
| MAH, country: | Sandoz Pharmaceuticals d.d., Slovenia | ||||||||||
| Therapeutic Class: | 59 - IMMUNOPRAEPARATA | ||||||||||
| ATC: |
|
||||||||||
| Shelf life: | 36 | ||||||||||
| Container: | blister OPA/Al/PVC/Al | ||||||||||
| Route of admin.: | Oral use |
| Prescription Status: | Medicinal product subject to restricted medical prescription. |
| Legal basis: | Article 10(1) generic application |
| MA issued: | 27.09.2018 |
| PIL: |
PIL_Lenalidomid_Sandoz_10 mg_15 mg_25 mg_11.2023.pdf
|
| SPC: |
SPC_Lenalidomid Sandoz_10 mg_15 mg_25 mg_07.2024.pdf
|
| Dokument: |
Lenalidomid_Príručka pre zdravotníckych pracovníkov.pdf
|
| Dokument: |
Lenalidomid_Príručka pre pacientov.pdf
|
| Dokument: |
Lenalidomid_Karta_pacienta.pdf
|
| Dokument: |
Lenalidomid_Formulár informovanosti o rizikách.pdf
|
| Safety feature | Yes |
| Data update: | 24.04.2023 |
